



Syndax Pharmaceuticals, Inc.
Investor Relations Department
35 Gatehouse Drive
Building D, Floor 3
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SNDX

Last Trade:	13.22
Trade Time:	4:00 PM ET 06.23.17
Change:	-0.02 (-0.151%)
Day Range	12.55 - 13.51
52-Week Range	6.31 - 18.03
Volume	652,513


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05.24.17 [Syndax Prices Public Offering of Common Stock](#)
- 05.23.17 [Syndax Announces Proposed Public Offering of Common Stock](#)
- 05.17.17 [Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® \(pembrolizumab\) for the Treatment of Advanced Melanoma](#)
- 05.16.17 [Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies](#)
- 05.15.17 [Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference](#)

Financial Information [\[View all \]](#)

- [First Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)
- 11.14.16 [Quarterly Report \(10-Q\)](#)
- 08.15.16 [Quarterly Report \(10-Q\)](#)